Mohammad Tabrizi

1.8k total citations
26 papers, 1.3k citations indexed

About

Mohammad Tabrizi is a scholar working on Radiology, Nuclear Medicine and Imaging, Molecular Biology and Immunology. According to data from OpenAlex, Mohammad Tabrizi has authored 26 papers receiving a total of 1.3k indexed citations (citations by other indexed papers that have themselves been cited), including 16 papers in Radiology, Nuclear Medicine and Imaging, 12 papers in Molecular Biology and 11 papers in Immunology. Recurrent topics in Mohammad Tabrizi's work include Monoclonal and Polyclonal Antibodies Research (16 papers), Protein purification and stability (7 papers) and Biosimilars and Bioanalytical Methods (6 papers). Mohammad Tabrizi is often cited by papers focused on Monoclonal and Polyclonal Antibodies Research (16 papers), Protein purification and stability (7 papers) and Biosimilars and Bioanalytical Methods (6 papers). Mohammad Tabrizi collaborates with scholars based in United States, United Kingdom and Iran. Mohammad Tabrizi's co-authors include Lorin Roskos, Gadi Gazit Bornstein, Saling Huang, Gregory Bell, Donald A. Mahler, David C. Blakey, Scott L. Klakamp, T Yi, Wentian Yang and Karim Berrada and has published in prestigious journals such as SHILAP Revista de lepidopterología, Blood and Analytical Chemistry.

In The Last Decade

Mohammad Tabrizi

26 papers receiving 1.2k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Mohammad Tabrizi United States 14 554 460 389 354 202 26 1.3k
Makoto Kamachi Japan 23 717 1.3× 397 0.9× 520 1.3× 161 0.5× 154 0.8× 55 1.9k
Sharlene Adams United States 16 525 0.9× 641 1.4× 998 2.6× 747 2.1× 83 0.4× 44 2.0k
Craig J. Reist United States 17 361 0.7× 626 1.4× 245 0.6× 492 1.4× 260 1.3× 27 1.4k
Erik R Vossenaar Netherlands 16 724 1.3× 920 2.0× 584 1.5× 399 1.1× 155 0.8× 16 2.7k
Brian M. Nolen United States 21 547 1.0× 127 0.3× 282 0.7× 577 1.6× 138 0.7× 28 1.6k
M. Forni Switzerland 16 371 0.7× 789 1.7× 188 0.5× 419 1.2× 104 0.5× 35 1.4k
Dan Combs United States 8 335 0.6× 383 0.8× 193 0.5× 233 0.7× 143 0.7× 10 1.2k
Denis Cournoyer Canada 23 708 1.3× 304 0.7× 279 0.7× 434 1.2× 56 0.3× 42 1.5k
Agnes S. Lo United States 20 418 0.8× 97 0.2× 599 1.5× 505 1.4× 109 0.5× 28 1.4k
Masazumi Takahashi Japan 27 435 0.8× 160 0.3× 488 1.3× 479 1.4× 1.3k 6.4× 106 2.4k

Countries citing papers authored by Mohammad Tabrizi

Since Specialization
Citations

This map shows the geographic impact of Mohammad Tabrizi's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Mohammad Tabrizi with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Mohammad Tabrizi more than expected).

Fields of papers citing papers by Mohammad Tabrizi

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Mohammad Tabrizi. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Mohammad Tabrizi. The network helps show where Mohammad Tabrizi may publish in the future.

Co-authorship network of co-authors of Mohammad Tabrizi

This figure shows the co-authorship network connecting the top 25 collaborators of Mohammad Tabrizi. A scholar is included among the top collaborators of Mohammad Tabrizi based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Mohammad Tabrizi. Mohammad Tabrizi is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Tabrizi, Reza, et al.. (2020). Penetrating Orbital Injury; a Case Report and Treatment Algorithm.. SHILAP Revista de lepidopterología. 8(1). e33–e33. 4 indexed citations
2.
Rosen, David B., Burkhardt Laufer, Thomas A. Knappe, et al.. (2020). Abstract 4507: TransConTM IL-2 β/γ: a novel long-acting prodrug of receptor-biased IL-2 designed for improved pharmocokinetics and optimal activation of T cells for the treatment of cancer. Cancer Research. 80(16_Supplement). 4507–4507. 1 indexed citations
3.
Tabrizi, Mohammad, Harish Shankaran, Veronica Juan, et al.. (2019). Pharmacokinetic Properties of Humanized IgG1 and IgG4 Antibodies in Preclinical Species: Translational Evaluation. The AAPS Journal. 21(3). 39–39. 10 indexed citations
4.
Tabrizi, Mohammad, et al.. (2018). Integrative Pharmacology: Advancing Development of Effective Immunotherapies. The AAPS Journal. 20(4). 66–66. 3 indexed citations
5.
Sadekar, Shraddha, Isabel Figueroa, & Mohammad Tabrizi. (2015). Antibody Drug Conjugates: Application of Quantitative Pharmacology in Modality Design and Target Selection. The AAPS Journal. 17(4). 828–836. 21 indexed citations
6.
Fazilaty, Hassan, et al.. (2013). Cancer metastasis, genetic and microenvironmental factors of distant tissue: a review article. SHILAP Revista de lepidopterología. 70(11). 671–683. 1 indexed citations
7.
Azadmehr, Abbas, et al.. (2013). Salivary soluble receptor activator of nuclear factor kappa B ligand/osteoprotegerin ratio in periodontal disease and health. Journal of Periodontal & Implant Science. 43(5). 227–227. 11 indexed citations
8.
Chesebrough, Jon, Sally‐Ann Ricketts, Margaret H. Veldman-Jones, et al.. (2011). Dual IGF-I/II–Neutralizing Antibody MEDI-573 Potently Inhibits IGF Signaling and Tumor Growth. Cancer Research. 71(3). 1029–1040. 105 indexed citations
9.
Brown, Jeffrey L., Zhe Cao, Maria Pinzon-Ortiz, et al.. (2010). A Human Monoclonal Anti-ANG2 Antibody Leads to Broad Antitumor Activity in Combination with VEGF Inhibitors and Chemotherapy Agents in Preclinical Models. Molecular Cancer Therapeutics. 9(1). 145–156. 113 indexed citations
10.
Tabrizi, Mohammad, Bing Wang, Hong Lü, et al.. (2010). Population Pharmacokinetic Evaluation of a Fully Human IgG2 Monoclonal Antibody in Patients with Inflammatory Diseases. Inflammation & Allergy - Drug Targets. 9(4). 229–237. 13 indexed citations
11.
Tabrizi, Mohammad, et al.. (2010). Application of Quantitative Pharmacology in Development of Therapeutic Monoclonal Antibodies. The AAPS Journal. 12(4). 592–601. 18 indexed citations
12.
Bornstein, Gadi Gazit, Scott L. Klakamp, Laura Andrews, William J. Boyle, & Mohammad Tabrizi. (2009). Surrogate approaches in development of monoclonal antibodies. Drug Discovery Today. 14(23-24). 1159–1165. 15 indexed citations
13.
Bornstein, Gadi Gazit, Christophe Quéva, Mohammad Tabrizi, et al.. (2009). Development of a new fully human anti-CD20 monoclonal antibody for the treatment of B-cell malignancies. Investigational New Drugs. 28(5). 561–574. 20 indexed citations
14.
Tabrizi, Mohammad, Gadi Gazit Bornstein, Scott L. Klakamp, et al.. (2009). Translational strategies for development of monoclonal antibodies from discovery to the clinic. Drug Discovery Today. 14(5-6). 298–305. 23 indexed citations
15.
Tabrizi, Mohammad, et al.. (2009). Biodistribution Mechanisms of Therapeutic Monoclonal Antibodies in Health and Disease. The AAPS Journal. 12(1). 33–43. 220 indexed citations
16.
Buckley, Lorrene A., Karen Davis‐Bruno, Gregory L. Finch, et al.. (2008). Nonclinical Aspects of Biopharmaceutical Development: Discussion of Case Studies at a PhRMA-FDA Workshop. International Journal of Toxicology. 27(4). 303–312. 12 indexed citations
17.
Bornstein, Gadi Gazit, Christophe Quéva, Mohammad Tabrizi, et al.. (2007). Development of a New Fully Human Anti-CD20 Monoclonal Antibody for the Treatment of B-Cell Malignancies.. Blood. 110(11). 2349–2349. 1 indexed citations
18.
Klakamp, Scott L., et al.. (2007). Application of Analytical Detection Concepts to Immunogenicity Testing. Analytical Chemistry. 79(21). 8176–8184. 16 indexed citations
19.
Tabrizi, Mohammad, et al.. (2006). Elimination mechanisms of therapeutic monoclonal antibodies. Drug Discovery Today. 11(1-2). 81–88. 367 indexed citations
20.
Mahler, Donald A., Saling Huang, Mohammad Tabrizi, & Gregory Bell. (2004). Efficacy and Safety of a Monoclonal Antibody Recognizing Interleukin-8 in COPD. CHEST Journal. 126(3). 926–934. 198 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Makoto Kamachi Breakdown of academic impact, for papers by Sharlene Adams Breakdown of academic impact, for papers by Craig J. Reist Breakdown of academic impact, for papers by Erik R Vossenaar Breakdown of academic impact, for papers by Brian M. Nolen Breakdown of academic impact, for papers by M. Forni Breakdown of academic impact, for papers by Dan Combs Breakdown of academic impact, for papers by Denis Cournoyer Breakdown of academic impact, for papers by Agnes S. Lo Breakdown of academic impact, for papers by Masazumi Takahashi
Rankless by CCL
2026